GP2 and AMP PD: Platform Partners for Progress in Parkinson’s Research
Adding a layer of compute to connect two massive datasets is where we are headed. Mike Nalls, Hampton Leonard, Matt Bookman, and Eline Appelmans outline the partnership between The Global Parkinson’s Genetics Program (GP2) and Accelerating Medicines Partnership: Parkinson's Disease (AMP PD) to be your one-stop shop for PD genetic and genomic data in this new blog post.
Open Science Opens Doors
By Bradford Casey | GP2 Values |In GP2, underlying data, analytical processes, and results will be made available to the research community as quickly as possible, with minimal barriers to access and use. The latest blog post by Bradford Casey highlights the value and importance of open science.
A letter to the patient community from Randy Schekman, ASAP Scientific Director
By Randy Schekman and Benjamin Stecher | GP2 Values |ASAP Scientific Director, Randy Schekman, expresses his personal and professional connection with Parkinson's disease in a letter to the patient community, shared by patient advocate Benjamin Stecher.
A Blueprint for Training and Development in GP2
By Alastair Noyce and Sara Bandres-Ciga | GP2 Values |Training is a crucial element of GP2. In this blog post, Alastair Noyce, Sara Bandres-Ciga and Emily Fisher outline the program's training and development goals.
Why study disease in different populations?
GP2 aims to revolutionize our understanding of the genetics of Parkinson's disease across populations. Ignacio 'Nacho' Mata explains the importance of involving populations currently underserved in disease research.